+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

PD-1 Resistant Head and Neck Cancer (HNC) - Epidemiology Forecast 2030

  • ID: 5387723
  • Drug Pipelines
  • July 2021
  • Region: Global
  • 130 pages
  • DelveInsight
This ‘PD-1 Resistant Head and Neck Cancer - Epidemiology Forecast - 2030' report deliver an in-depth understanding of and historical and forecasted epidemiology of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, South Korea, and Taiwan.

PD-1 Resistant Head and Neck Cancer Disease Understanding


Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease encompassing various tumors that originate in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. The disease group as a whole is associated with different epidemiology, etiology, and therapy. Worldwide, it represents the sixth most common neoplasia and accounts for 6% of all cases, being responsible approximately for 1-2% of tumor deaths. Given the complexities of head and neck cancer (HNC), treatment decisions have to be taken by multidisciplinary teams (MDTs) with training not only in treatment but also in supportive care (considering swallowing, nutritional, dental, and voice impairment due to the effects of clinical intervention).

The three main types of treatment for managing head and neck cancer were radiation therapy, surgery, and chemotherapy. However, the survival rate for head and neck cancer is quite low due to its ability to evade the immune response. Immune escape and T-cell exhaustion are mechanisms used by Head and Neck cancer for cancer survival in the tumor microenvironment. Several immune checkpoint inhibitors have been approved for cancer which has significantly improved the survival rate. However, they are associated with various side effects. Hence, the current approach focuses on novel therapeutics that can also bypass the mechanism that leads to relapse in this cancer while improving the survival rate.

PD-1 Resistant Head and Neck Cancer Epidemiology


The PD-1 Resistant Head and Neck Cancer epidemiology division provide insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings


The total incident cases of PD-1 Resistant Head and Neck Cancer patients are increasing in the studied geography during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted PD-1 Resistant Head and Neck Cancer symptoms epidemiology segmented as the Head and Neck Cancer diagnoses patients, PD-1 treated patients and PD-1 refractory patients. The report includes the prevalent scenario of PD-1 Resistant Head and Neck Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea and Taiwan from 2018 to 2030.

Country-wise PD-1 resistant patients Epidemiology


The epidemiology segment also provides the IO treated patients epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea and Taiwan.

The total cases of PD-1 resistant patients in the covered geographies were 11,940 in 2020.
  • As per the estimates, the United States has the largest population of PD-1 resistant patients.
  • Among the EU5 countries, France had the highest cases of PD-1 resistant patients. On the other hand, Spain had the lowest cases of PD-1 resistant patients in 2020.

Scope of the Report

  • The PD-1 Resistant Head and Neck Cancer report cover a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The PD-1 Resistant Head and Neck Cancer epidemiology report and model provide an overview of PD-1 Resistant Head and Neck Cancer's risk factors and global trends in the ten major markets (US, France, Germany, Italy, Spain, UK, Japan, China, South Korea and Taiwan).
  • The report provides insight into PD-1 Resistant Head and Neck Cancer's historical and forecasted patient pool in ten major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, China, South Korea and Taiwan.
  • The report helps to recognize the growth opportunities in the covered geographies concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of PD-1 Resistant Head and Neck Cancer.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by Head and Neck cancer diagnosed patients in 7MM, China, South Korea and Taiwan.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 treated patients in 7MM, China, South Korea and Taiwan.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 refractory patients in 7MM, China, South Korea and Taiwan.

Report Highlights

  • 10-year Forecast of PD-1 Resistant Head and Neck Cancer epidemiology
  • 7MM, China, South Korea and Taiwan Coverage
  • Head and Neck cancer diagnosed patients.
  • PD-1 treated patients.
  • PD-1 resistant patients.

KOL Views


The publisher interviews KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the covered geographies7MM, China, South Korea and Taiwan for the patient population about PD-1 Resistant Head and Neck Cancer?
  • What are the key findings of the PD-1 Resistant Head and Neck Cancer epidemiology across 7MM, China, South Korea and Taiwan, and which country will have the highest number of patients during the study period (2018-2030)?
  • What would be the total number of PD-1 Resistant Head and Neck Cancer patients across 7MM, China, South Korea and Taiwan during the study period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?
  • At what CAGR the patient population is expected to grow in 7MM, China, South Korea and Taiwan during the study period (2018-2030)?
  • What are the disease risk, burdens, and unmet needs of PD-1 Resistant Head and Neck Cancer?
  • What are the currently available treatments for PD-1 Resistant Head and Neck Cancer?

Reasons to Buy


The PD-1 Resistant Head and Neck Cancer epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global PD-1 Resistant Head and Neck Cancer market.
  • Quantify patient populations in the global PD-1 Resistant Head and Neck Cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD-1 Resistant Head and Neck Cancer therapeutics in each of the markets covered.
  • Understand the magnitude of the PD-1 Resistant Head and Neck Cancer population by its diagnosed cases.
  • Understand the magnitude of the PD-1 Resistant Head and Neck Cancer population by PD-1 treated patients.
  • Understand the magnitude of the PD-1 Resistant Head and Neck Cancer population by PD-1 resistant patients.
  • The PD-1 Resistant Head and Neck Cancer epidemiology report and model were written and developed by masters and Ph.D. level epidemiologists.
  • The PD-1 Resistant Head and Neck Cancer epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China
  • South Korea
  • Taiwan
Study Period: 2018-2030

The epidemiology for cancer in the 7MM (United States, Germany, France, Italy, Spain, the United Kingdom, and Japan), China, South Korea and Taiwan was determined based on primary and secondary data collected through various sources. The report's epidemiology sections rely on the current data from Cancer Tomorrow to provide a comprehensive understanding of the disease burden. Along with this, nationwide studies conducted in the 7MM region and expert estimations were also used.

As per Haslam and Prasad (2019), the estimated percentage of patients with cancer who were eligible for checkpoint inhibitor drugs increased from 1.54% in 2011 to 43.63% in 2018. The percentage of patients with cancer was 0.14% in 2011 that was estimated to respond to checkpoint inhibitor drugs when ipilimumab was approved for unresectable or metastatic melanoma, which increased to 5.86% by 2015. By 2018, the estimated percentage of responders increased to 12.46%.

Another report by Hepp et al. (2021) published a study from the United States that showed higher rates, with 7.9%, 57.8%, and 64.4% of patients receiving IO in first, second, and third lines, respectively. It was observed that the use of IO was higher in later lines of therapy, ranging from 1.4% to 7.9% as first-line therapy to 57.8% as second-line and 64.4% as third-line therapy. In contrast, the percentage of patients receiving subsequent therapy after discontinuing IO reported in studies by Barata et al. (2018), and Sonpavde et al. (2017) ranged from 25.0% to 35.5%.

These and other such articles and KOL views were considered while estimating the portion of patients on checkpoint inhibitors and the share of patients that relapse or are refractory to currently approved checkpoint inhibitors.
Note: Product cover images may vary from those shown
1 Key Insights

2 Report Introduction

3 PD-1 Resistant Head and Neck Cancer Market Overview at a Glance
3.1 Patient Share (%) Distribution of PD-1 Resistant Head and Neck Cancer in 2018
3.2 Market Share (%) Distribution of PD-1 Resistant Head and Neck Cancer in 2030

4 Executive Summary of PD-1 Resistant Head and Neck Cancer

5 Disease Background and Overview
5.1 Pathogenesis
5.2 Molecular Genetics of Head and Neck Cancer
5.3 Types of Head and Neck Cancer
5.4 Symptoms
5.5 Risk factors
5.6 Histopathology
5.7 Diagnosis
5.8 Staging
5.9 NCCN Guidelines
5.1 EHNSe-ESMOe-ESTRO Clinical Practice Guidelines for Squamous cell carcinoma
5.11 ESMO-EURACAN Clinical Practice Guidelines for Nasopharyngeal carcinoma

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 PD-1 refractory patients in 7MM, China, South Korea and Taiwan
6.3 Epidemiology of Checkpoint Inhibitors refractory cancer
6.4 The United States
6.4.1 Head and Neck cancer diagnosed patients in the United States
6.4.2 PD-1 treated patients in the United States
6.4.3 PD-1 refractory patients in the United States
6.5 EU5
6.5.1 Germany
6.5.2 France
6.5.3 Italy
6.5.4 Spain
6.5.5 United Kingdom
6.6 Japan
6.6.1 Head and Neck cancer diagnosed patients in Japan
6.6.2 PD-1 treated patients in Japan
6.6.3 PD-1 refractory patients in Japan
6.7 China
6.7.1 Head and Neck cancer diagnosed patients in China
6.7.2 PD-1 treated patients in China
6.7.3 PD-1 refractory patients in China
6.8 South Korea
6.8.1 Head and Neck cancer diagnosed patients in South Korea
6.8.2 PD-1 treated patients in South Korea
6.8.3 PD-1 refractory patients in South Korea
6.9 Taiwan
6.9.1 Head and Neck cancer diagnosed patients in Taiwan
6.9.2 PD-1 treated patients in Taiwan
6.9.3 PD-1 refractory patients in Taiwan

7 Appendix

8 Bibliography

9 Report Methodology

10 Publisher Capabilities

11 Disclaimer

12 About the Publisher

List of Tables
Table 1: Summary of PD-1/ PD-L1 Resistant Head and Neck Cancer, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Tumor-node Metastasis Classification of Human Papillomavirus (HPV)-Positive and HPV-Negative Oropharyngeal Cancer
Table 3: Prognostic Stages According to the TNM Classification*
Table 4:Work-up for staging and diagnosis
Table 5:Management of oral cavity cancer (stage I-IVB) excluding lip carcinoma
Table 6:Management of laryngeal cancer (stage I-IVB)
Table 7:Management of oropharyngeal cancer (p16-negative stage I-IVB; p16-positive stage I-III)
Table 8: Management of hypopharyngeal cancer (stage I-IVB)
Table 9: Management of recurrent and/or metastatic disease not amenable to curative RT or surgery
Table 10:Diagnostic work-up
Table 11: Total PD-1 refractory population in 7MM, China, South Korea and Taiwan (2018-2030)
Table 12: Incidence of Head and Neck cancer in the United States (2018-2030)
Table 13: PD-1 treated patients in the United States (2018-2030)
Table 14: PD-1 refractory patients in the United States (2018-2030)
Table 15: Incidence of Head and Neck cancer in Germany (2018-2030)
Table 16: PD-1 treated patients in Germany (2018-2030)
Table 17: PD-1 refractory patients in Germany (2018-2030)
Table 18: Incidence of Head and Neck cancer in France (2018-2030)
Table 19: PD-1 treated patients in France (2018-2030)
Table 20: PD-1 refractory patients in France (2018-2030)
Table 21: Incidence of Head and Neck cancer in Italy (2018-2030)
Table 22: PD-1 treated patients in Italy (2018-2030)
Table 23: PD-1 refractory patients in Italy (2018-2030)
Table 24: Incidence of Head and Neck cancer in Spain (2018-2030)
Table 25: PD-1 treated patients in Spain (2018-2030)
Table 26: PD-1 refractory patients in Spain (2018-2030)
Table 27: Incidence of Head and Neck cancer in the United Kingdom (2018-2030)
Table 28: PD-1 treated patients in the United Kingdom (2018-2030)
Table 29: PD-1 refractory patients in the United Kingdom (2018-2030)
Table 30: Incidence of Head and Neck cancer in Japan (2018-2030)
Table 31: PD-1 treated patients in Japan (2018-2030)
Table 32: PD-1 refractory patients in Japan (2018-2030)
Table 33: Incidence of Head and Neck cancer in China (2018-2030)
Table 34: PD-1 treated patients in China (2018-2030)
Table 35: PD-1 refractory patients in China (2018-2030)
Table 36: Incidence of Head and Neck cancer in South Korea (2018-2030)
Table 37: PD-1 treated patients in South Korea (2018-2030)
Table 38: PD-1 refractory patients in South Korea (2018-2030)
Table 39: Incidence of Head and Neck cancer in Taiwan (2018-2030)
Table 40: PD-1 treated patients in Taiwan (2018-2030)
Table 41: PD-1 treated patients in Taiwan (2018-2030)

List of Figures
Figure 1: Histologic features of head and neck squamous cell carcinoma (HNSCC)
Figure 2: Updates in version 1.2021 of the NCCN guidelines for Head and Neck Cancers from version 2.2020 include:
Figure 3: Updates in version 1.2021 of the NCCN guidelines for Head and Neck Cancers from version 2.2020 include:
Figure 4: Treatment algorithm for stage I-IVA NPC
Figure 5: Treatment algorithm for recurrent and/or metastatic NPC
Figure 6: Total PD-1 refractory population in 7MM, China, South Korea and Taiwan (2018-2030)
Figure 7: Incidence of Head and Neck cancer in the United States (2018-2030)
Figure 8: PD-1 treated patients in the United States (2018-2030)
Figure 9: PD-1 refractory patients in the United States (2018-2030)
Figure 10: Incidence of Head and Neck cancer in Germany(2018-2030)
Figure 11: PD-1 treated patients in Germany (2018-2030)
Figure 12: PD-1 refractory patients in Germany (2018-2030)
Figure 13: Incidence of Head and Neck cancer in France(2018-2030)
Figure 14: PD-1 treated patients in France (2018-2030)
Figure 15: PD-1 refractory patients in France (2018-2030)
Figure 16: Incidence of Head and Neck cancer in Italy(2018-2030)
Figure 17: PD-1 treated patients in Italy (2018-2030)
Figure 18: PD-1 refractory patients in Italy (2018-2030)
Figure 19: Incidence of Head and Neck cancer in Spain(2018-2030)
Figure 20: PD-1 treated patients in Spain (2018-2030)
Figure 21: PD-1 refractory patients in Spain (2018-2030)
Figure 22: Incidence of Head and Neck cancer in the United Kingdom (2018-2030)
Figure 23: PD-1 treated patients in the United Kingdom (2018-2030)
Figure 24: PD-1 refractory patients in the United Kingdom (2018-2030)
Figure 25: Incidence of Head and Neck cancer in Japan (2018-2030)
Figure 26: PD-1 treated patients in Japan (2018-2030)
Figure 27: PD-1 refractory patients in Japan (2018-2030)
Figure 28: Incidence of Head and Neck cancer in China (2018-2030)
Figure 29: PD-1 treated patients in China (2018-2030)
Figure 30: PD-1 refractory patients in China (2018-2030)
Figure 31: Incidence of Head and Neck cancer in South Korea (2018-2030)
Figure 32: PD-1 treated patients in South Korea (2018-2030)
Figure 33: PD-1 refractory patients in South Korea (2018-2030)
Figure 34: Incidence of Head and Neck cancer in Taiwan (2018-2030)
Figure 35: PD-1 treated patients in Taiwan (2018-2030)
Figure 36: PD-1 refractory patients in Taiwan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll